annual EBITDA:
$1.29B-$199.71M(-13.38%)Summary
- As of today (September 12, 2025), RPRX annual EBITDA is $1.29 billion, with the most recent change of -$199.71 million (-13.38%) on December 31, 2024.
- During the last 3 years, RPRX annual EBITDA has fallen by -$161.27 million (-11.09%).
- RPRX annual EBITDA is now -51.18% below its all-time high of $2.65 billion, reached on December 31, 2019.
Performance
RPRX EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly EBITDA:
$159.30M-$339.39M(-68.06%)Summary
- As of today (September 12, 2025), RPRX quarterly EBITDA is $159.30 million, with the most recent change of -$339.39 million (-68.06%) on June 30, 2025.
- Over the past year, RPRX quarterly EBITDA has dropped by -$84.09 million (-34.55%).
- RPRX quarterly EBITDA is now -89.49% below its all-time high of $1.52 billion, reached on December 31, 2019.
Performance
RPRX quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
$1.93B-$84.09M(-4.17%)Summary
- As of today (September 12, 2025), RPRX TTM EBITDA is $1.93 billion, with the most recent change of -$84.09 million (-4.17%) on June 30, 2025.
- Over the past year, RPRX TTM EBITDA has increased by +$714.67 million (+58.76%).
- RPRX TTM EBITDA is now -35.36% below its all-time high of $2.99 billion, reached on September 30, 2020.
Performance
RPRX TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
RPRX EBITDA Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
---|---|---|---|
1 y1 year | -13.4% | -34.5% | +58.8% |
3 y3 years | -11.1% | -70.4% | +75.9% |
5 y5 years | -51.2% | -75.2% | -32.0% |
RPRX EBITDA Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
---|---|---|---|---|---|---|---|
3 y | 3-year | -13.4% | +39.2% | -81.8% | +128.3% | -4.2% | +355.8% |
5 y | 5-year | -51.2% | +39.2% | -81.8% | +128.3% | -35.4% | +355.8% |
alltime | all time | -51.2% | +63.4% | -89.5% | +128.3% | -35.4% | +355.8% |
RPRX EBITDA History
Date | Annual | Quarterly | TTM |
---|---|---|---|
Jun 2025 | - | $159.30M(-68.1%) | $1.93B(-4.2%) |
Mar 2025 | - | $498.69M(+24.6%) | $2.02B(+29.5%) |
Dec 2024 | $1.29B(-13.4%) | $400.11M(-54.2%) | $1.56B(-19.0%) |
Sep 2024 | - | $872.86M(+258.6%) | $1.92B(+57.9%) |
Jun 2024 | - | $243.39M(+509.1%) | $1.22B(-11.3%) |
Mar 2024 | - | $39.96M(-94.8%) | $1.37B(-27.3%) |
Dec 2023 | $1.49B(+60.7%) | $764.84M(+355.0%) | $1.89B(+237.4%) |
Sep 2023 | - | $168.11M(-57.8%) | $559.36M(-15.1%) |
Jun 2023 | - | $398.29M(-28.4%) | $658.64M(-17.6%) |
Mar 2023 | - | $556.04M(-198.8%) | $798.92M(+88.6%) |
Dec 2022 | $928.56M(-36.1%) | -$563.08M(-310.6%) | $423.69M(-61.2%) |
Sep 2022 | - | $267.39M(-50.4%) | $1.09B(-0.4%) |
Jun 2022 | - | $538.56M(+197.9%) | $1.10B(-22.1%) |
Mar 2022 | - | $180.82M(+69.9%) | $1.41B(-1.5%) |
Dec 2021 | $1.45B | $106.44M(-60.9%) | $1.43B(-17.5%) |
Date | Annual | Quarterly | TTM |
---|---|---|---|
Sep 2021 | - | $271.92M(-68.0%) | $1.73B(-18.3%) |
Jun 2021 | - | $849.91M(+320.6%) | $2.12B(+10.9%) |
Mar 2021 | - | $202.06M(-50.7%) | $1.92B(+1.8%) |
Dec 2020 | $1.62B(-38.9%) | $410.27M(-38.0%) | $1.88B(-37.0%) |
Sep 2020 | - | $661.49M(+3.1%) | $2.99B(+5.2%) |
Jun 2020 | - | $641.90M(+281.1%) | $2.84B(+15.8%) |
Mar 2020 | - | $168.41M(-88.9%) | $2.45B(-10.9%) |
Dec 2019 | $2.65B(+89.4%) | $1.52B(+194.5%) | $2.75B(+122.4%) |
Sep 2019 | - | $514.62M(+102.9%) | $1.24B(+71.1%) |
Jun 2019 | - | $253.67M(-46.0%) | $723.63M(+54.0%) |
Mar 2019 | - | $469.96M | $469.96M |
Dec 2018 | $1.40B(+43.7%) | - | - |
Dec 2017 | $972.96M(+23.0%) | - | - |
Dec 2016 | $791.08M(-8.3%) | - | - |
Dec 2015 | $862.44M | - | - |
FAQ
- What is Royalty Pharma plc annual EBITDA?
- What is the all time high annual EBITDA for Royalty Pharma plc?
- What is Royalty Pharma plc annual EBITDA year-on-year change?
- What is Royalty Pharma plc quarterly EBITDA?
- What is the all time high quarterly EBITDA for Royalty Pharma plc?
- What is Royalty Pharma plc quarterly EBITDA year-on-year change?
- What is Royalty Pharma plc TTM EBITDA?
- What is the all time high TTM EBITDA for Royalty Pharma plc?
- What is Royalty Pharma plc TTM EBITDA year-on-year change?
What is Royalty Pharma plc annual EBITDA?
The current annual EBITDA of RPRX is $1.29B
What is the all time high annual EBITDA for Royalty Pharma plc?
Royalty Pharma plc all-time high annual EBITDA is $2.65B
What is Royalty Pharma plc annual EBITDA year-on-year change?
Over the past year, RPRX annual EBITDA has changed by -$199.71M (-13.38%)
What is Royalty Pharma plc quarterly EBITDA?
The current quarterly EBITDA of RPRX is $159.30M
What is the all time high quarterly EBITDA for Royalty Pharma plc?
Royalty Pharma plc all-time high quarterly EBITDA is $1.52B
What is Royalty Pharma plc quarterly EBITDA year-on-year change?
Over the past year, RPRX quarterly EBITDA has changed by -$84.09M (-34.55%)
What is Royalty Pharma plc TTM EBITDA?
The current TTM EBITDA of RPRX is $1.93B
What is the all time high TTM EBITDA for Royalty Pharma plc?
Royalty Pharma plc all-time high TTM EBITDA is $2.99B
What is Royalty Pharma plc TTM EBITDA year-on-year change?
Over the past year, RPRX TTM EBITDA has changed by +$714.67M (+58.76%)